Authors
No matching authors found
Try adjusting your search criteria
Advertisement
Advertisement
Trending on BioPharm International
1
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
4
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
5